Epigenomics AG / Key word(s): Agreement 09.01.2014 / 08:30 Berlin, Germany, Germantown, MD, U.S.A. and Wuhan and Beijing, China, January 9, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), a German-American cancer molecular diagnostics company, and Wuhan Kindstar Clinical Diagnostics Co. Ltd (Kindstar), a leading Chinese clinical diagnostics company, announced today that both […]
Category: Press Releases
09. January 2014
Epigenomics AG: Epigenomics signs licensing and supply agreement with Kindstar for Epi proLung in China
Read more
12. December 2013
Epigenomics AG: Epigenomics AG Welcomes Reimbursement for Septin9 Testing by French Insurance Provider
Epigenomics AG / Key word(s): Miscellaneous 12.12.2013 / 08:45 Berlin, Germany, and U.S.A., December 12, 2013 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced that MACSF (Mutuelle d’Assurance du Corps de Santé Français), the leading French supplementary insurance provider for the medical community, will provide the […]
04. December 2013
Epigenomics AG: Epigenomics AG Secures Additional Financing
Epigenomics AG / Key word(s): Corporate Action 04.12.2013 / 09:20 Berlin, Germany, and U.S.A., December 4, 2013 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced that it has obtained a commitment for an additional financing. Through the issuance of convertible bonds, the Company will immediately receive […]
27. November 2013
Epigenomics AG: Epigenomics AG Announces FDA Advisory Committee Meeting to Review Epi proColon(R)
Epigenomics AG / Key word(s): Miscellaneous 27.11.2013 / 16:30 Berlin, Germany, and U.S.A., November 27, 2013 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced that the Company was informed by the U.S. Food and Drug Administration (FDA) via the premarket approval (PMA) review process for Epi […]
20. November 2013
Epigenomics AG: Epigenomics’ methylated SHOX2 Biomarker shows promising results for Therapy Monitoring of Lung Cancer Patients
Epigenomics AG / Key word(s): Study 20.11.2013 / 15:15 Methylated SHOX2 allows rapid and sensitive determination of tumor response and therapy monitoring in plasma of lung cancer patients Multi-centric study with larger patient population planned for verification Further demonstrates commercial value of Epigenomics’ DNA methylation platform Berlin, Germany and U.S.A., November 20, 2013 – Epigenomics […]
06. November 2013
Epigenomics AG: Epigenomics AG Announces 2013 Third Quarter and Nine Month Financial Results and Reports on Operational Highlights
Epigenomics AG / Key word(s): Quarter Results 06.11.2013 / 08:30 Berlin, Germany, and U.S.A., November 6, 2013 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced its financial results for the third quarter and the nine months ending September 30, 2013. 9M 2013 revenue increased by 43% […]